Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer.

The Breast : Official Journal of the European Society of Mastology
Robert S Kerbel

Abstract

One of the major recent clinical advances in cancer treatment is the use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib. Bevacizumab, the monoclonal anti-VEGF antibody, has been approved for the first line treatment of metastatic breast cancer (MBC) when combined with taxane. However, the clinical benefits are modest; despite a doubling of response rates and significant prolongation of progression free survival times, no increase in overall survival is attained. This review summarizes some of the possibilities to account for this discrepant result. These include rapid development of acquired drug resistance due to the redundancy of proangiogenic growth factors, acceleration of tumor growth after antiangiogenic drug treatments are stopped, and increases in tumor cell malignant aggressiveness driven by mechanisms such as increased tumor hypoxia. Some possible strategies to improve the benefits of antiangiogenic drug therapy are discussed such as prolonging the treatment beyond tumor progression, combination with other therapeutic modalities, e.g. long term ('maintenance') low-dose metronomic chemotherapy or additional targeted/biologic drugs, e.g. trastuzumab.

References

Jan 1, 1991·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·R S Kerbel
Apr 20, 2000·The Journal of Clinical Investigation·D HanahanE Bergsland
Sep 27, 2000·Neoplasia : an International Journal for Oncology Research·J L RubensteinM A Shuman
Feb 23, 2002·Science·Joanne L YuRobert S Kerbel
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ColleoniA Goldhirsch
Oct 3, 2002·Biochemical and Biophysical Research Communications·Takeshi NatoriMasatoshi Makuuchi
Jun 6, 2003·Nature·Donald P Bottaro, Lance A Liotta
Jul 2, 2003·Nature Medicine·Patricia S Steeg
Oct 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Guido BocciRobert S Kerbel
Apr 23, 2004·The New England Journal of Medicine·Harubumi KatoUNKNOWN Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Nov 10, 2004·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Julia Glade BenderDarrell J Yamashiro
Nov 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristian Pietras, Douglas Hanahan
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo
Apr 2, 2005·Nature Reviews. Cancer·Michael DeanSusan Bates
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hedy L KindlerEverett E Vokes
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerBrian I Rini
Jan 13, 2006·Nature Clinical Practice. Oncology·Rakesh K JainJay S Loeffler
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeanne M du ManoirRobert S Kerbel
Jul 14, 2006·Nature Reviews. Cancer·Adrian M JubbHartmut Koeppen
Jul 22, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sylvia S W NgRobert S Kerbel
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alberto BottiniAlfredo Berruti
Oct 4, 2006·The Journal of Clinical Investigation·Michael R MancusoDonald M McDonald
May 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anat Norden-ZfoniJohn V Heymach
Oct 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·John M L EbosRobert S Kerbel
Dec 8, 2007·Nature·Farbod ShojaeiNapoleone Ferrara
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Agustin A GarciaAmit M Oza
Mar 4, 2008·Nature Cell Biology·Héctor Peinado, Amparo Cano
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinKathy D Miller
May 9, 2008·The New England Journal of Medicine·Robert S Kerbel
Jul 25, 2008·Nature Reviews. Cancer·Gabriele Bergers, Douglas Hanahan
Aug 8, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W CacheuxF Goldwasser
Aug 16, 2008·The New England Journal of Medicine·Gianpaolo ZerbiniAlessio Palini
Sep 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia DellapasquaMarco Colleoni

❮ Previous
Next ❯

Citations

Jan 13, 2011·Cancer Research·Evan T Keller, Lu-Yuan Li
Aug 2, 2014·Cancer Chemotherapy and Pharmacology·Dominique BarbolosiFabrice Barlesi
Oct 24, 2015·European Journal of Pharmacology·Sai-Wang SetoDennis Chang
Apr 12, 2011·Journal of Surgical Oncology·Tanja HolopainenAnne Saaristo
Apr 27, 2011·Journal of Cellular Physiology·Marta De DonatoCristiano Ferlini
May 3, 2016·Cell Reports·Laura PisarskyGerhard Christofori
Apr 26, 2017·World Journal of Clinical Oncology·Viviana Masoud, Gilles Pagès
Aug 23, 2012·British Journal of Cancer·A GiatromanolakiUNKNOWN Tumour and Angiogenesis Research Group
Feb 23, 2012·Cancer Research·Christina S F WongAndreas Möller
Apr 5, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Anahita AbdaliStefano Bellosta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.